Covered recipient · General Payments record
BENJAMIN HUMPHREYS
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
General Payments · PY2020–2024
$13,202.03
- Reported across 12 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,256.00 | 1 |
| Travel and Lodging | $683.78 | 2 |
| Food and Beverage | $440.33 | 6 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $5,939.78 | 3 |
| CALLIDITAS THERAPEUTICS US INC. | $254.26 | 3 |
| Retrophin, Inc. | $145.59 | 1 |
| Collegium Pharmaceutical, Inc. | $40.48 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $493.13 | 02/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1117584161 | CMS |
| Amgen Inc. | $190.65 | 02/12/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1117584159 | CMS |
| Amgen Inc. | $5,256.00 | 02/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1117584157 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $29.54 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141508519 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $126.46 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141508521 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $98.26 | 08/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141520171 | CMS |
| Collegium Pharmaceutical, Inc. | $23.17 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135318725 | CMS |
| Collegium Pharmaceutical, Inc. | $17.31 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135339075 | CMS |
| Travere Therapeutics, Inc. | $145.59 | 09/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149959900 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.